TY - JOUR
T1 - Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by Shiga-like toxin-liposome conjugate
AU - Fukuda, Tadashi
AU - Kimiya, Takako
AU - Takahashi, Motohide
AU - Arakawa, Yoshichika
AU - Ami, Yasushi
AU - Suzaki, Yuriko
AU - Naito, Seishiro
AU - Horino, Atsuko
AU - Nagata, Noriyo
AU - Satoh, Sachihiro
AU - Gondaira, Fumio
AU - Sugiyama, Jun Ichi
AU - Nakano, Yoshio
AU - Mori, Masahito
AU - Nishinohara, Shouichi
AU - Komuro, Katsutoshi
AU - Uchida, Tetsuya
PY - 1998/8
Y1 - 1998/8
N2 - We have previously reported that purified Shiga-like toxins (SLT), SLT-I and SLT-II coupled with liposomes induced a substantial amount of anti-SLT-I and anti-SLT-II IgG antibody production, respectively, in mice. The levels of anti-SLT antibody in the sera of SLT-liposome-immune mice correlated well with the protection against subsequent challenge with SLT. In this study, mice were immunized intraperitoneally with the mixture of SLT-I-liposome and SLT-II-liposome and protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 was evaluated. All of the mice that received immunization with the mixture of SLT-I-liposome and SLT-II-liposome were protected against subsequent intravenous challenge with 10 LD50 of either SLT-I or SLT-II. Eight weeks after primary immunization, mice were inoculated intragastrically with 109 CFU of E. coli O157:H7 strain 96-60. All SLT-liposome-immune mice tested survived without any apparent symptom while control mice died within 5 days. In addition, as shown by other antigen-liposome conjugates, SLT-liposome induced undetectable anti-SLT IgE antibody production while they induced substantial amounts of anti-SLT IgG antibodies. These results suggest that SLT-liposome conjugate may serve as a candidate vaccine that induces protection against cytotoxin-producing E. coli infection.
AB - We have previously reported that purified Shiga-like toxins (SLT), SLT-I and SLT-II coupled with liposomes induced a substantial amount of anti-SLT-I and anti-SLT-II IgG antibody production, respectively, in mice. The levels of anti-SLT antibody in the sera of SLT-liposome-immune mice correlated well with the protection against subsequent challenge with SLT. In this study, mice were immunized intraperitoneally with the mixture of SLT-I-liposome and SLT-II-liposome and protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 was evaluated. All of the mice that received immunization with the mixture of SLT-I-liposome and SLT-II-liposome were protected against subsequent intravenous challenge with 10 LD50 of either SLT-I or SLT-II. Eight weeks after primary immunization, mice were inoculated intragastrically with 109 CFU of E. coli O157:H7 strain 96-60. All SLT-liposome-immune mice tested survived without any apparent symptom while control mice died within 5 days. In addition, as shown by other antigen-liposome conjugates, SLT-liposome induced undetectable anti-SLT IgE antibody production while they induced substantial amounts of anti-SLT IgG antibodies. These results suggest that SLT-liposome conjugate may serve as a candidate vaccine that induces protection against cytotoxin-producing E. coli infection.
UR - http://www.scopus.com/inward/record.url?scp=7344224899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7344224899&partnerID=8YFLogxK
U2 - 10.1159/000023961
DO - 10.1159/000023961
M3 - Article
C2 - 9693282
AN - SCOPUS:7344224899
SN - 1018-2438
VL - 116
SP - 313
EP - 317
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
IS - 4
ER -